Distribuzione geografica
Continente #
NA - Nord America 19.635
EU - Europa 6.989
AS - Asia 2.186
SA - Sud America 36
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 8
Totale 28.897
Nazione #
US - Stati Uniti d'America 19.398
IT - Italia 1.391
IE - Irlanda 1.376
SE - Svezia 1.263
CN - Cina 1.212
DE - Germania 985
UA - Ucraina 693
HK - Hong Kong 532
GB - Regno Unito 360
CA - Canada 234
FI - Finlandia 205
VN - Vietnam 159
FR - Francia 153
RU - Federazione Russa 150
AT - Austria 135
TR - Turchia 96
IN - India 88
DK - Danimarca 70
BE - Belgio 56
NL - Olanda 56
JP - Giappone 28
SG - Singapore 27
BR - Brasile 21
EU - Europa 16
BG - Bulgaria 15
GR - Grecia 13
IR - Iran 13
CH - Svizzera 11
ES - Italia 11
NO - Norvegia 11
RO - Romania 11
AR - Argentina 9
KR - Corea 8
AU - Australia 7
EG - Egitto 6
MU - Mauritius 6
PL - Polonia 6
CZ - Repubblica Ceca 5
CL - Cile 4
PT - Portogallo 4
RE - Reunion 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
IL - Israele 3
PH - Filippine 3
UZ - Uzbekistan 3
KZ - Kazakistan 2
MX - Messico 2
RS - Serbia 2
SA - Arabia Saudita 2
SC - Seychelles 2
TW - Taiwan 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BY - Bielorussia 1
GL - Groenlandia 1
HU - Ungheria 1
ID - Indonesia 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
TG - Togo 1
VE - Venezuela 1
Totale 28.897
Città #
Ann Arbor 3.634
Fairfield 2.292
Woodbridge 2.114
Houston 1.638
Dublin 1.344
Chandler 1.252
Ashburn 1.101
Wilmington 1.058
Seattle 865
Cambridge 798
Jacksonville 755
Frankfurt am Main 750
Dearborn 605
New York 534
Hong Kong 530
Princeton 492
Milan 352
Lawrence 239
Altamura 224
Nanjing 223
Beijing 154
San Diego 147
Vienna 133
Shanghai 132
Lachine 124
Dong Ket 80
Andover 79
Nanchang 77
Lissone 72
Helsinki 69
Shenyang 63
Toronto 62
Fuzhou 58
Guangzhou 56
Hebei 55
Rome 55
Brussels 52
Boardman 50
Jinan 48
Changsha 46
Tianjin 46
Norwalk 41
London 37
Falls Church 34
Jiaxing 32
Ningbo 29
Zhengzhou 28
Hangzhou 26
Besana In Brianza 25
Fremont 25
Pune 25
Ottawa 24
Redmond 24
Kocaeli 23
Kunming 23
Mountain View 23
Chicago 22
Huizen 20
Paris 18
Göttingen 17
Hefei 17
San Mateo 17
Monza 16
Turin 15
Bologna 14
Edmonton 13
Grafing 13
Sesto San Giovanni 13
Taizhou 13
Athens 11
Brugherio 11
Nürnberg 11
Padova 11
Washington 11
Hounslow 10
Los Angeles 10
Perugia 10
Carate Brianza 9
Leawood 9
Mariano Comense 9
Oslo 9
Allentown 8
Auburn Hills 8
University Park 8
Bonndorf 7
Cinisello Balsamo 7
Mumbai 7
Phoenix 7
Plovdiv 7
Rho 7
Sacramento 7
São Paulo 7
Amsterdam 6
Changchun 6
Chengdu 6
Gap 6
Haikou 6
Kiev 6
Kurume 6
Prescot 6
Totale 23.334
Nome #
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 321
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 296
NIPBL: a new player in myeloid cells differentiation 295
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 277
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 270
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 267
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 256
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 251
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 242
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 225
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 223
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 222
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 216
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 214
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 210
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 210
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 205
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 203
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 201
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 192
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 185
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 183
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 183
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 182
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 181
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 180
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 179
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 179
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 178
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 178
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 177
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 177
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 177
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 175
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 175
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 175
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 173
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 173
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 172
CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies 172
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 172
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 168
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 168
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 163
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 162
Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions 162
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 160
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 159
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 159
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 158
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 156
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 156
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis 155
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 155
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 154
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 153
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 153
Rings and bricks: Expression of cohesin components is dynamic during development and adult life 153
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 152
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 152
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 151
TEL/ARG induces cytoskeletal abnormalities in 293T cells 151
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol 150
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 149
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 149
Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia 148
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 148
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 148
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 146
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 146
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 145
Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients 143
In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice 141
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 141
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 141
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 140
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 140
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 139
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 139
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 139
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 138
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 137
Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Ph– B-Cell Precursor Acute Lymphoblastic Leukemia 136
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 136
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 136
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 136
The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia 135
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 135
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 133
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 132
Metabolic gatekeeper function of B-lymphoid transcription factors 132
T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses 131
Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing 131
Loss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemia 130
PAX5 Fusion Genes Activate The STAT5 Signaling Pathway Through Lck Over-Expression 130
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia 130
Somatic PTPN11 mutations in childhood acute myeloid leukaemia 129
SSBP2-CSF1R is a Recurrent Fusion in B-lineage Acute Lymphoblastic Leukaemia with Diverse Genetic Presentation and Variable Outcome 129
Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia 128
Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses 127
Totale 17.065
Categoria #
all - tutte 92.488
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.488

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.903 0 0 0 0 0 0 0 0 0 349 743 811
2019/20206.135 727 350 408 607 651 776 796 450 553 343 317 157
2020/20215.491 222 341 432 474 446 436 816 678 399 494 350 403
2021/20223.278 232 342 419 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20243.587 119 130 173 185 528 1.087 816 152 357 40 0 0
Totale 30.008